9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
Open accessThe DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc20-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the demonstrated benefits of SGLT2 inhibitors, the updated American Diabetes Association guidelines10 and the American College of Cardiology expert consensus statement11 now recommend their use for diabetic patients who have or are at high risk for cardiovascular disease, CKD, or heart failure regardless of current glycemic control.”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [10]
In the citing paper
“All recommend SGLT2 inhibition for patients with T2DM and eGFR as low as 30 mL/min/1.73 m2, particularly if severely increased albuminuria is present.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“Major national and international organizations are rapidly updating recommendations and guidelines (Table 4) (85–88).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [85]
In the citing paper
“In the US, the 2020 national median drug acquisition cost of GLP-1RAs ranges from $634 per month to $835 per month,27·41 although the out-of-pocket cost borne by patients varies considerably by insurance formulary and coverage.”
From Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review (2020) · cites this paper as [27]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“may reduce risk of cardiovascular events and death (35).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682 · cited 1×
“first-line therapy hasbeneficial effects on A1C, weight, and cardiovascular mortality (36); there is little systematic data”
BackgroundThreshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“with type 1 diabetes (15,16), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (17).”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Items 701–800 of 958
Sitagliptin-Induced Arthralgias: A Case Report
Jackson, R., Sbeiti, I., & Vincent, G. (2020) · Clinical Diabetes · doi:10.2337/cd19-0023 · Cited by 2
Changing Fields-Diabetes Medications Invading the Cardiovascular Space
Breite, L. D., Steck, M., Cutshall, B. T., Shah, S. P., & Cave, B. E. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100736 · Cited by 3
SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
Raschi, E., Fadini, G. P., Diemberger, I., Poluzzi, E., & Ponti, F. D. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1846719 · Cited by 2
Zeidan, T., NIKKEL, C. C., Dziengelewski, B., Wu, S., & Chen, A. M. H. (2020) · Pharmacy · doi:10.3390/pharmacy8040215 · Cited by 2
Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use
Davis, H., Heilmann, R. M. F., Milchak, J. L., & Delate, T. (2021) · Family Practice · doi:10.1093/fampra/cmab021 · Cited by 2
Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift
Maranta, F., Cianfanelli, L., Gaspardone, C., Rizza, V., Grippo, R., Ambrosetti, M., & Cianflone, D. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.05.050 · Cited by 2
Maleš, V. K., & Požar, M. (2021) · ACS Omega · doi:10.1021/acsomega.1c01744 · Cited by 2
Hubbard, D. M., McKinley, E., Colantonio, L. D., Poudel, B., Rosenson, R. S., Brown, T. M., Jackson, E. A., Huang, L., Orroth, K. K., Mues, K. E., et al. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100121 · Cited by 3
“…on diabetes, pre-diabetes, and cardiovascular diseases and the 2020 American Diabetes Association clinical practice recommendations, initiation of an SGLT2i is reasonable for patients with diabetes who have established ASCVD as part of their glucose-lowering regimen and to lower ASCVD risk [6,8].”
BackgroundFrancisco, M. D., Magnaye, F. M., Molina, A. J. R., & Sandoval, M. A. (2022) · Acta Medica Philippina · doi:10.47895/amp.v56i6.2992 · Cited by 2
Bae, J., Kim, Y.-E., Lee, M., Lee, Y., Lee, B., Soo, B., & Kang, E. S. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.6.539 · Cited by 2
Zhang, J., Xian, T.-Z., Teng, Y., Wang, X., Wu, M.-X., Li, C., Wang, W., Man, F., Zhang, X., Wang, X., et al. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/7128859 · Cited by 2
Lifestyle and Dietary Modifications: Relevance in the Management of Diabetic Neuropathy
Enders, J. D., & Wright, D. E. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_22 · Cited by 3
Supabphol, S., Wattanasukchai, L., Nasomjit, S., Seubwai, W., Wongkham, S., & Saengboonmee, C. (2023) · Gene Expression · doi:10.14218/ge.2022.00006s · Cited by 3
Naz, F., Qadir, R., Baammi, S., Ali, A., & Rehman, M. U. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15336-5.00012-9 · Cited by 2
Antsiferov, M. B., Kantemirova, M. A., Demidov, N. A. D., & Kalashnikova, M. F. (2023) · Diabetes Mellitus · doi:10.14341/dm12962 · Cited by 2
Pandya, N., & Patel, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_38 · Cited by 2
NF-kappa B signaling pathway is associated with metformin resistance in type 2 diabetes patients
Mansouri, V., Bandarian, F., Razi, F., Razzaghi, Z., Tavirani, M. R., Rezaei, M. S., Arjmand, B., & Rezaei–Tavirani, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01458-8 · Cited by 2
“Metformin is an essential medicine introduced by the world health organization for type 2 diabetes (T2D and the most widely prescribed frontline for the treatment of this disease [2].”
Dose Accuracy and Reliability of a Connected Insulin Pen System
Backfish, M., Kovalchick, K., Albert, R., Rosilio, M., Chigutsa, F. B., & Liao, B. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241301760 · Cited by 4
Khoshnazar, S. M., Shabanzadeh, R., & Yousefzadeh, G. (2025) · Diabetes Mellitus · doi:10.14341/dm13153 · Cited by 2
Bonilla-Bonilla, J. D., Chávez-Sanchéz, L., & Legorreta-Haquet, M. V. (2025) · Boletín Médico del Hospital Infantil de México · doi:10.24875/bmhim.24000174 · Cited by 2
Insulin degludec/liraglutide in type 2 diabetes: a profile of its use
Heo, Y. (2020) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00731-z · Cited by 3
Alkagiet, S., & Τζιόμαλος, Κ. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i5.150 · Cited by 2
Salahuddin, T., Richardson, V. L., McNeal, D. M., Henderson, K., Hess, P. L., Raghavan, S., Saxon, D. R., Valle, J. A., Waldo, S. W., Ho, P. M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14193 · Cited by 2
Relationship of Glucose Variability and Daily Lifestyle by Continuous Glucose Monitoring (CGM)
Yamashita, H., Kato, Y., Bando, H., Kanazawa, S., Tanaka, M., Sueki, E., Kanagawa, H., Kawata, T., Kawahito, A., Aihara, A., et al. (2020) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2020/asjbccr.6213 · Cited by 2
Bossi, A. C., Mori, V. D., Scaranna, C., Veronesi, G., Lepore, G., the ANDREW study group, Barbara, A., Rosalia, B., Antonio, B., Berzi, D., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00929-4 · Cited by 2
Estrategia terapéutica en el paciente diabético (III). Insulinoterapia
Ocaña, P. G., Cobos-Palacios, L., Muriel, C. C., & Jansen‐Chaparro, S. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.021 · Cited by 2
Modesto, A. C. F., Silveira, É. A., Rodrigues, A. P. D. S., Lima, D. M., Provin, M. P., & Amaral, R. G. (2020) · Scientia Pharmaceutica · doi:10.3390/scipharm88040048 · Cited by 3
Generette, G. S., Bachul, P. J., Gołąb, K., Basto, L., Pyda, J. S., Anteby, R., Borek, P., TIBUDAN, M. L., Perea, L., Charlton, M., et al. (2020) · European Journal of Translational and Clinical Medicine · doi:10.31373/ejtcm/130187 · Cited by 2
Takehisa, Y., & Bando, H. (2020) · doi:10.36502/2020/droa.6174 · Cited by 3
Unexpected adverse event of insulin therapy in diabetes mellitus
Borro, M., Murdaca, G., Monachesi, M., & Negrini, S. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01674-1 · Cited by 2
Metformin in the Era of New Antidiabetics
Al-Mahdi, E. A. R., Barrios, V., & Zamorano, J. L. (2021) · Future Cardiology · doi:10.2217/fca-2020-0195 · Cited by 2
Bando, H. (2021) · Edelweiss Journal of Biomedical Research and Review · doi:10.33805/2690-2613.118 · Cited by 2
Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes
Kheloussi, S. S., Johns, A. M., Parente, V., McLay, W., & Gionfriddo, M. R. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.7.846 · Cited by 2
Çakmak, R., Çaklılı, Ö. T., Tekin, S., Hacışahinoğulları, H., Tanrıkulu, S., Koc, M. S., & Dınççağ, N. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0318 · Cited by 2
Nashawi, M., Ahmed, M. S., Amin, T., Abualfoul, M., & CHILTON, R. J. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i12.676 · Cited by 2
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Pham, N.-Y. T., Argyropoulos, C., & Dinh, N. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_27 · Cited by 2
Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes
Malik, M. E., Andersson, C., Blanche, P., D’Souza, M., Madelaire, C., Zareini, B., Lamberts, M., Kristensen, S. L., Sattar, N. A., McMurray, J. J. V., et al. (2022) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02016-z · Cited by 2
Schreiber, C. D. S., Rafacho, A., Silvério, R., Betti, R., Lerário, A. C., Lotenberg, A. M. P., Rahmann, K., de Oliveira, C. P., WAJCHENBERG, B. L., & da Luz, P. L. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000478 · Cited by 2
Kim, H. S., Yu, J. M., Jang, H. C., Choi, E. K., Park, J. H., Shon, H. S., Chung, C. H., Park, K., Cho, J., Kim, W., et al. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s334944 · Cited by 2
Wolf, R. A., HAW, J. S., Martyn, K. K., & Kimble, L. P. (2022) · Clinical Diabetes · doi:10.2337/cd21-0075 · Cited by 2
Yao, J., Guo, X., Li, S., Han, P., Lv, X., Zhang, X., Mo, Z., Yang, W., Zhang, L., Wang, Z., et al. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2100652 · Cited by 3
Insulin Therapy in Type 2 Diabetes Mellitus
(2022) · The Singapore Family Physician · doi:10.33591/sfp.48.1.u2 · Cited by 2
Diabetes and Erectile Dysfunction
Bearelly, P., Moore, S. A., Avellino, G., & Ko, D. S. C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_20 · Cited by 2
Evaluation of the safety of inpatient empagliflozin in a real-world setting
Bicker, A., Tatara, A. W., Solomon, E. J., & Ji, C. S. (2023) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2023.2248866 · Cited by 2
Pharmacotherapy of Type 2 Diabetes Mellitus
Jha, P. K., Shukla, H., Makwana, A., & Kakkad, A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002309 · Cited by 4
Rezaeianzadeh, R., & Sadatsafavi, M. (2024) · Thorax · doi:10.1136/thorax-2024-222540 · Cited by 3
An overview of the once‐weekly GLP‐1 receptor agonists from the pharmacist’s perspective
Patel, D. K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13227 · Cited by 1
Kaneto, H., Baxter, M., Takahashi, Y., & Terauchi, Y. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02311-1 · Cited by 1
Does Serum R-Spondin-1 Play a Role in PCOS Pathophysiology?
Başpınar, O., Şimşek, Y., Koçer, D., Dizdar, O. S., & TOPALOĞLU, H. K. (2022) · Genel Tıp Dergisi · doi:10.54005/geneltip.1111079 · Cited by 1
Whitley, H. P., & Smith, W. D. (2023) · Journal of Case Reports and Images in Medicine · doi:10.5348/100073z09hw2022cs · Cited by 1
Tanveer, Y., Sanipini, S., Khleif, R., Tsenteradze, T., Gapizov, A., Grezenko, H., Affaf, M., Abdelaziz, A., Rehman, A., Zia, U., et al. (2023) · Cureus · doi:10.7759/cureus.46998 · Cited by 2
Fernández-Crespo, S., Vázquez-Agra, N., Marques-Afonso, A.-T., Cruces‐Sande, A., Olmos, M. Á. M., Araújo‐Vilar, D., & Ameijeiras, Á. H. (2023) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2023.11.002 · Cited by 1
Choi, J. S., Ma, D., Wolfson, J. A., Wyman, J. F., Adam, T. J., & Fu, H. N. C. (2023) · CIN Computers Informatics Nursing · doi:10.1097/cin.0000000000001073 · Cited by 1
Associated Factors Related to Self-Management Behaviors among People with Type 2 Diabetes in Myanmar
Oo, A., Lininger, J., & Leelacharas, S. (2023) · Makara Journal of Health Research · doi:10.7454/msk.v27i3.1459 · Cited by 3
Royo, J. H., Mera-Gallego, I., Ríos-Quintás, R. M., Fornos-Pérez, J. A., Andrés-Iglesias, J. C., & Rodríguez, N. F. A. (2024) · Farmacéuticos Comunitarios · doi:10.33620/fc.2173-9218.(2024).26 · Cited by 1
“Un grupo de expertos en el uso de medicamentos antidiabéticos realizó modifica-ciones en el cuestionario basadas en las recomendaciones sobre uso y técnicas de inyección de insulina [1,11-14] y pilotó la viabilidad de su administración.”
BackgroundMorrell, A. T., Shelofsky, S., Hoffman, H., McCallister, C., Huff, T. W., Schabel, K., O’Glasser, A. Y., & Kagan, R. P. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-091446 · Cited by 1
Current Evidence on SGLT‐2 Inhibitors in Prediabetes: A Review of Preclinical and Clinical Data
Pourkarim, F., Entezari‐Maleki, T., & Rezaee, H. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70026 · Cited by 1
Zeng, Y., Ye, Y., Li, Y., Yuan, M., & Hu, J. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0711 · Cited by 1
Fujita, S., Nagata, K., Kinjo, K., Mimata, H., Sonoda, T., Mine, K., Kawashiri, T., Hirota, T., Uchida, M., & Kobayashi, D. (2025) · Clinical and Translational Science · doi:10.1111/cts.70423 · Cited by 1
Surina, S., Scisciola, L., Basilicata, M. G., Pesapane, A., Fontanella, R. A., Balzano, N., Palazzo, A., Zia, A., Tortorella, G., Ulfat, Z., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07959-9 · Cited by 3
Gao, Q., Li, Y., & Wang, L. (2026) · Food Reviews International · doi:10.1080/87559129.2026.2642794 · Cited by 3
“[41,68,69] Mechanistically, HCDs alter intracellular fatty acid partitioning by suppressing mitochondrial β-oxidation (via downregulation of carnitine palmitoyltransferase 1, CPT1) and promoting triacylglycerol (TAG) synthesis.”
Barsukova, A. D., Weng, L., Szymanska-Vandendriessche, K. J., Scott, M., Langer, R., & Traverso, G. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114914 · Cited by 1
Mlčůchová, N., Lipový, B., Zendulka, O., Janošek, J., & Linhartová, P. B. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1794405 · Cited by 1
“Metformin is the drug of choice in patients with newly diagnosed Type 2 diabetes mellitus (T2DM) (Bailey, 2017; Flory and Lipska, 2019), typically administered in monotherapy along with recommendations for lifestyle modifications (American Diabetes Association, 2020).”
Estrategia terapéutica en el paciente diabético (II). Hipoglucemiantes orales. Consejos al paciente
Hernández, E. L., Jiménez, P. G., & Mancebo-Sevilla, J. J. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.020 · Cited by 1
Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
Newman, C. B., Saunders, K. H., & Subramanian, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816569-0.00009-7 · Cited by 1
New perspectives on insulin therapy
Araki, E., Araki, H., Senokuchi, T., & Motoshima, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13263 · Cited by 1
Ogiso, K., Koriyama, N., Obo, T., Tokito, A., & Nishio, Y. (2020) · Diabetology International · doi:10.1007/s13340-020-00457-3 · Cited by 1
Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure
Schumacher, C., Dril, E. V., Shealy, K. M., & Goldman, J. D. (2020) · Clinical Diabetes · doi:10.2337/cd20-0008 · Cited by 1
Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers
Gunning, K. M. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.9.1077 · Cited by 2
Cowart, K., Updike, W. H., Lloyd, A., & Bullers, K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13270 · Cited by 2
Dawra, V. K., Pelletier, K. B., Matschke, K. T., Shi, H., Hickman, A., Zhou, S., Krishna, R., & Sahasrabudhe, V. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.884 · Cited by 1
Xue, L., Strotmeyer, E. S., Zgibor, J. C., Costacou, T., Boudreau, R. M., Kelley, D., & Donohue, J. M. (2020) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2020.100241 · Cited by 1
Inflammatory Mechanisms in Diabetic Kidney Disease
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_32 · Cited by 1
Neto, F. L., Mendes, T. B., de Matos, P. M. P. G., de Oliveira, J. C., Favarato, M. H. S., Lin, C. A., & Martins, M. A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14303 · Cited by 1
Timar, B., Braha, A., Grigorică, L., Gaiţă, L., & Timar, R. Z. (2020) · Timişoara Medical Journal · doi:10.35995/tmj20200101 · Cited by 1
Rosenstock, J., Blonde, L., Aroda, V. R., Frías, J. P., Souhami, E., Ji, C. F., Niemoeller, E., & Prato, S. D. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14345 · Cited by 1
Cohen, C. M., Hallén, N., Chodick, G., Bourvine, L., Waner, T., & Karasik, A. (2021) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00268-5 · Cited by 1
Adverse Effects of Medications on Micronutrient Status: From Evidence to Guidelines
Daniels, M. S., Park, B. I., & McKay, D. L. (2021) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-120420-023854 · Cited by 2
Chen-Ku, C. H., de Sucre, P. G., Vinocour, M., Ramírez-Zamora, L. C., Andrés-Jiménez, F., Slon-Hitti, C., Cob, A., & Rodríguez, G. (2021) · Cureus · doi:10.7759/cureus.16060 · Cited by 1
Bailey, T. S., Evenou, P., Gill, J., Berhanu, P., Raymond, R., Strong, J. L., & Wright, E. E. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0079 · Cited by 1
Manejo ambulatorio del paciente con diabetes en tiempos de COVID-19
Rincón, A. R., & Builes-Montaño, C. E. (2020) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.7.2s.587 · Cited by 1
Kim, S. S., & Kim, I. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_9 · Cited by 1
Bongaerts, B. W. C., Kollhorst, B., Kuß, O., Pigeot, I., & Rathmann, W. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1702-5151 · Cited by 1
Saudi Consensus for GLP-1 RAs Switching Guidance: Consensus Report
Alsifri, S. N., Elbadawi, H., Alsabaan, F., Almahfouz, A., Alyahya, K. A., Shesha, E., Esba, L. C. A., Alnais, M., Aldahash, R., Alharbi, T., et al. (2022) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2022.131002 · Cited by 1
Alatawi, A. M. (2022) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2022/v34i7b35470 · Cited by 1
New therapies for diabetes mellitus
Barbieri, M., Cataldo, V., Griffing, G. T., & Paolisso, G. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch87 · Cited by 1
Uso inicial de insulina en pacientes hospitalizados con diabetes mellitus tipo 2
Díaz, J. J. S., Arias, L. O. M., Murcia, A. M. P., Díaz, A. L. A., Ângulo, P. S., Roa, D. E. M., & Orjuela, A. M. (2022) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.8.4.714 · Cited by 1
Lane, W. S., Favaro, E., Jódar, E., Kelkar, P., Oviedo, A., Sivarathinasami, R., Senior, P. A., Sesti, G., & Franek, E. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01213-3 · Cited by 1
Schernthaner-Reiter, M. H., Wolf, P. S., Vila, G., & Luger, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819949-7.00037-8 · Cited by 2
Sethi, B. K., Chowdhury, S., Bhattacharya, S., Katare, S., Suryawanshi, S. Y., & Barkate, H. V. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01074-3 · Cited by 2
Ковальчук, А., Зінич, О., Prybyla, О. В., Кushnareva, N. M., Ковальчук, В. М., & Shyshkan-Shyshova, К. О. (2022) · World Science · doi:10.31435/rsglobal_ws/30042022/7803 · Cited by 1
Sodium–glucose co-transporter-2 inhibitors
Lee, M. M. Y., Docherty, K. F., & Jhund, P. S. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780198766223.003.0051 · Cited by 1
A glorious past, dynamic present and a promising future: Insulin at 100
Sharma, J. K., Sharma, D., & Gupta, A. S. (2022) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715221088981 · Cited by 1
Kadowaki, T., Shoji, A., & Taguchi, Y. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13872 · Cited by 1
Icodec insulin - revolution in diabetes type 2 insulin therapy
Dobrzyński, M., Czarnota, J., Skubel, T., Drozd, M., Dudek, I., & Rybak, N. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.08.097 · Cited by 1
Efficacy of semaglutide: an evidence-based review
Mkrtumyan, A. M., & Egshatyan, L. V. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2022-010 · Cited by 2
Abdelfattah, O., Sayed, A., Al-Refaei, A., Abdeldayem, J., Moustafa, K., Elias, N., & Saleh, Y. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070008 · Cited by 1
How SGLT2 inhibitors interact with metformin? A molecular dynamics study
Maleš, V. K., & Požar, M. (2023) · Molecular Simulation · doi:10.1080/08927022.2023.2196346 · Cited by 1
Pharmacoeconomic evaluation of insulin aspart and glargine in type 1 and 2 diabetes mellitus in Iran
Nosrati, M., Fariman, S., Saiyarsarai, P., & Nikfar, S. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01209-1 · Cited by 2
Type 2 Diabetes and Pre-Diabetes in Pediatric Obesity
Bensignor, M. O. (2023) · Springer eBooks · doi:10.1007/978-3-031-37380-0_9 · Cited by 1
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-16
- Volume
- 43
- Issue
- Supplement_1
- Pages
- S98-S110
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4246340431
- Cited by
- 914
- References
- 84
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 69 · 2023: 100 · 2022: 151 · 2021: 270 · 2020: 268
- FWCI
- 140.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Glycemic Control, Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Hypoglycemic Agents, Reference Standards, Societies, Medical, United States, History, 21st Century, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.